Clinical trials: Movement; Disorder, Treatment-Induced
Stroke, Healthy
Use of Transcranial Direct Current Stimulation (tDCS) Coupled With Constraint Induced Movement Therapy in Stroke Patient
The purpose of this study is to determine whether noninvasive brain stimulation associated with motor learning offers an additional benefit than motor learning alone in patients with stroke.
- Trial name
- tdcs (NCT01143649)
- Testing
- transcranial direct current stimulation (tDCS), constraint induced movement therapy (CIMT), transcranial alternating current stimulation (tACS)
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Spaulding Rehabilitation Hospital
Parkinson Disease
A Study to Assess the Safety and Effectiveness of Pridopidine Compared to Placebo in the Treatment of Levodopa-Induced Dyskinesia in Patients With Parkinson's Disease
This is a multicenter, randomized, three-arm, parallel-group, double-blind, placebo-controlled, study to evaluate the efficacy, safety and pharmacokinetics (PK) of pridopidine vs.
- Trial name
- NCT03922711
- Testing
- Pridopidine
- Where
- 33 sites in United States
- Volunteers
- 23 people
- Sponsor
- Prilenia
Stroke, Hemiplegia
Brain Stimulation and Rehabilitation for Adults With Chronic, Severe Arm Motor Impairment After Stroke
This pilot study will examine a combination therapy for adults with chronic, severe motor impairment of an arm after stroke. The intervention will combine brain stimulation with physical rehabilitation of the arm on the side of…
- Conditions
- Stroke, Hemiplegia, Hemiparesis
- Trial name
- NCT03538795
- Testing
- iTBS&eCIMT
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Alabama at Birmingham
Tardive Dyskinesia
Aim to Reduce Movements in Tardive Dyskinesia
The purpose of this study is to determine whether an investigational drug, SD-809 (deutetrabenazine), will reduce the severity of abnormal involuntary movements of tardive dyskinesia.
- Trial name
- ARM-TD (NCT02195700)
- Testing
- SD-809
- Where
- 41 sites in United States, Czechia and 2 more
- Volunteers
- 117 people
- Sponsor
- Auspex Pharmaceuticals, Inc.
Idiopathic Parkinson's Disease, Drug Induced Dyskinesia
Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease
The study will involve an eighteen-week, double-blind, placebo-controlled parallel designed comparison between add-on topiramate and add-on placebo to stable treatment with amatadine in the treatment of Parkinson's disease (PD)…
- Trial name
- TOP-DYSK (NCT01789047)
- Testing
- Topiramate, Amantadine
- Where
- 5 sites in United States
- Volunteers
- 42 people
- Sponsor
- Rush University Medical Center
Tardive Dyskinesia
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
The purpose of this study is to evaluate the efficacy, safety, and tolerability of NBI-98854 administered once daily for the treatment of Tardive Dyskinesia (TD) symptoms.
- Trial name
- KINECT 3 (NCT02274558)
- Testing
- NBI-98854
- Where
- 54 sites in United States, Canada and 1 more
- Volunteers
- 234 people
- Sponsor
- Neurocrine Biosciences
Infant Development, Hemiplegia
CIMT and taVNS for Hemiplegia in Infants
Newborns who are born premature or suffer brain injury at birth are at risk for motor problems that may cause weakness in reaching and grasping on one side of the body.
- Conditions
- Infant Development, Hemiplegia, Constraint Induced Movement Therapy
- Trial name
- NCT05101707
- Testing
- transcutaneous auricular vagus nerve stimulation, Constraint induced movement therapy
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Medical University of South Carolina
Oral Dystonia, Tardive Dystonia
Dysport for the Treatment of OMD
The purpose of this study is to study the efficacy and safety of AbobotulinumtoxinA (Dysport) for use in Oromandibular Dystonia (OMD).
- Trial name
- NCT01921270
- Testing
- Low Dose - AbobotulinumtoxinA
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Emory University
Dyskinesia, Parkinson's Disease
Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients
To evaluate the efficacy, safety, and tolerability of AVP-923 capsules containing 45 mg dextromethorphan and 10 mg quinidine (AVP-923-45) compared to placebo for the treatment of levodopa-induced dyskinesia (LID) in patients with…
- Trial name
- LID in PD (NCT01767129)
- Testing
- AVP-923-45
- Where
- 3 sites in United States, Canada
- Volunteers
- 14 people
- Sponsor
- Avanir Pharmaceuticals
CVA (Cerebrovascular Accident), Stroke
Application of a Reimbursable Form of Constraint-Induced Movement Therapy for Upper Extremity
CI therapy is a family of techniques that has systematically applied intensive treatment daily over consecutive days, supervised motor training using a technique called shaping, behavioral strategies to improve the use of the…
- Conditions
- CVA (Cerebrovascular Accident), Stroke, Upper Extremity Paresis
- Trial name
- NCT05311384
- Testing
- Keys Constraint-induced Movement Therapy protocol
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Alabama at Birmingham
Tourette Syndrome, Tic Disorders
Median Nerve Stimulation Pilot
Results from the University of Nottingham suggested that rhythmic median nerve stimulation (MNS) improves tic symptoms in Tourette syndrome (TS).
- Conditions
- Tourette Syndrome, Tic Disorders, Tic Disorder, Chronic Motor or Vocal
- Trial name
- MNS (NCT04731714)
- Testing
- Rhythmic median nerve stimulation, Arrhythmic median nerve stimulation
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Washington University School of Medicine
Stroke, Hemiparesis
Effectiveness of Virtual Reality Gaming Therapy Versus CI Therapy for Upper Extremity Rehabilitation
The current proposal aims to conduct a multi-site randomized controlled trial comparing virtual-reality gaming delivery of Constraint Induced Movement therapy (CI therapy) with (1) traditional clinic-based CI therapy of equal…
- Trial name
- NCT02631850
- Testing
- Traditional CI Therapy, Gaming CI Therapy, Gaming CI Therapy with Additional Contact via Video Conference
- Where
- 5 sites in United States
- Volunteers
- 193 people
- Sponsor
- Ohio State University
Tardive Dyskinesia
NBI-98854 Dose Titration Study for the Treatment of Tardive Dyskinesia
The purpose of this study is to evaluate the efficacy, safety, and tolerability of NBI-98854 (titrated to a subject's optimal dose in the range of 25 to 75 mg) administered once daily for the treatment of Tardive Dyskinesia (TD)…
- Trial name
- NCT01733121
- Testing
- NBI-98854
- Where
- 22 sites in United States, Puerto Rico
- Volunteers
- 102 people
- Sponsor
- Neurocrine Biosciences
Tardive Dyskinesia
Efficacy and Safety of MT-5199 in Subjects With Tardive Dyskinesia
The purpose of this study is to evaluate the efficacy and safety of MT-5199 administered once daily for the treatment of Tardive Dyskinesia (TD) symptoms.
- Trial name
- NCT03176771
- Testing
- MT-5199
- Where
- 82 sites in Japan
- Volunteers
- 256 people
- Sponsor
- Tanabe Pharma Corporation
Akathisia, Drug-Induced, Antipsychotic Agents
Study of Preladenant for the Treatment of Neuroleptic Induced Akathisia (Study P05145)
This study is designed to evaluate the effectiveness of preladenant in the prevention (Part 1) or treatment (Part 2) of antipsychotic induced akathisia in participants with acute psychosis using the Barnes Akathisia Scale.
- Conditions
- Akathisia, Drug-Induced, Antipsychotic Agents, Movement Disorders
- Trial name
- NCT00693472
- Testing
- Preladenant, Anticholinergic agents or propanolol, Haloperidol
- Volunteers
- 46 people
- Sponsor
- Merck Sharp & Dohme LLC
Dyskinesia, Levodopa Induced Dyskinesia (LID)
Open-Label Safety Study of ADS-5102 in PD Patients With LID
This is a 105-week open-label study to evaluate the safety and tolerability of ADS-5102 oral capsules, an extended release formulation of amantadine, in Parkinson's Disease (PD) patients with Levodopa Induced Dyskinesia (LID).
- Conditions
- Dyskinesia, Levodopa Induced Dyskinesia (LID), Parkinson's Disease (PD)
- Trial name
- NCT02202551
- Testing
- ADS-5102
- Where
- 87 sites in United States, Austria and 4 more
- Volunteers
- 223 people
- Sponsor
- Adamas Pharmaceuticals, Inc.
Opioid Induced Constipation
To Evaluate Patient Preference of Movantik and Polyethylene Glycol 3350 for Opioid Induced Constipation
The purpose of this study is to determine whether patients with opioid induced constipation prefer treatment with naloxegol (Movantik) or with Polyethylene Glycol 3350.
- Trial name
- NCT03060512
- Testing
- Polyethylene Glycol 3350, Movantik
- Where
- 53 sites in United States
- Volunteers
- 276 people
- Sponsor
- AstraZeneca
Tardive Dyskinesia (TD)
Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia
This is a Phase 4, randomized, double-blind, placebo-controlled study to evaluate the persistence of effect of valbenazine 40 mg and 80 mg.
- Trial name
- NCT03891862
- Testing
- Valbenazine
- Where
- 43 sites in United States, Puerto Rico
- Volunteers
- 135 people
- Sponsor
- Neurocrine Biosciences
Cerebral Palsy Spastic Hemiplegic
Therapeutic Effects of Constraint-Induced Movement Therapy on Young Children With Cerebral Palsy
This study evaluates the therapeutic effects of constraint-induced movement therapy on infants and children with hemiplegic cerebral palsy.
- Trial name
- NCT03858335
- Testing
- Constraint-induced movement therapy
- Where
- South Korea
- Volunteers
- 32 people
- Sponsor
- Samsung Medical Center
Stroke
Improving Stroke Rehabilitation: Spacing Effect and D-cycloserine
Each year 730,000 Americans experience a stroke. Forty percent are left with significant paralysis of one arm. Certain types of physical therapy, for example constraint induced movement therapy (CIMT), have been shown to be…
- Trial name
- NCT00720759
- Testing
- D-cycloserine + distributed treatment, D-cycloserine + condensed treatment
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- US Department of Veterans Affairs